Are we prepared for the influx of CAR-Ts?
Chimeric antigen receptor (CAR)-T continues to take center stage as a paradigm shift in the treatment of cancer. The phrase ‘paradigm shift’ gets thrown about a lot in the discussion of new developments in medicine, but when it comes to CAR-T therapies we believe that it is really justified in this case, due to their potential to be transformative – as evidenced by Gilead’s December 2021 announcement that Yescarta shows durable long-term survival in patients with refractory large B-cell lymphoma.
However, will market access and hospital processes also need to transform to accommodate these therapies? In this issue of Free Thinking, we take a look.
Download the white paper.
Other insights.
Jump to a slide with the slide dots.
Reflecting on the latest developments in market access for advanced therapies
Tania Rodrigues reflects on sessions and roundtables from the conference where hot topics related to advanced therapies were discussed.
Read moreAdvanced Therapies 2023: The P&R/market access landscape for this modality still needs more adaptation
Learn what Tania Rodrigues found most impactful with regards to market access and pricing and reimbursement at the recent Advanced Therapies Congress.
Read moreSign up to receive Rapport.
Rapport is our monthly newsletter where we share our latest expertise and experience.